Search research articles
Contact Us
Filters
Showing results (21-30 of 46) with videos related to
Page
of 5
Sort By:
JACC. Cardiovascular Interventions
|
July 22, 2017
First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter
Matthew J Price, Shigeru Saito, Richard A Shlofmitz, et al.
Journal of the American Heart Association
|
June 15, 2026
Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED
David E Kandzari, Felix Mahfoud, Raymond R Townsend, et al.
The Journal of the Association of Physicians of India
|
September 10, 2016
Medical Management and Diagnostic Testing among Stable Angina Patients in India: The STable Angina obseRvational (STAR) Registry
Dev Pahlajani, Upendra Kaul, Anil Mishra, et al.
Circulation. Cardiovascular Interventions
|
May 20, 2025
Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial
David E Kandzari, Felix Mahfoud, Raymond R Townsend, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension
|
October 14, 2022
Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial
Kazuomi Kario, Felix Mahfoud, David E Kandzari, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
April 10, 2020
Correction to: Rationale and design of two randomized sham‑controlled of catheter‑based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN‑OFF MED Pivotal) and presence (SPYRAL HTN‑ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
Michael Böhm, Raymond R Townsend, Kazuomi Kario, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
February 9, 2020
Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
Michael Böhm, Raymond R Townsend, Kazuomi Kario, et al.
Lancet (London, England)
|
September 21, 2022
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial
Deepak L Bhatt, Muthiah Vaduganathan, David E Kandzari, et al.
American Heart Journal
|
June 17, 2019
Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy
Elvin Kedhi, Azeem Latib, Alexandre Abizaid, et al.
JACC. Heart Failure
|
March 27, 2025
Association of Extracoronary Calcification and Incident Heart Failure in the Multiethnic Study of Atherosclerosis (MESA)
Sandeep Brar, Rahul Goli, Joshua P Barrios, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 46) with videos related to
Sort By:
Page
of 5
JACC. Cardiovascular Interventions
|
July 22, 2017
First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter
Matthew J Price, Shigeru Saito, Richard A Shlofmitz, et al.
Journal of the American Heart Association
|
June 15, 2026
Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED
David E Kandzari, Felix Mahfoud, Raymond R Townsend, et al.
The Journal of the Association of Physicians of India
|
September 10, 2016
Medical Management and Diagnostic Testing among Stable Angina Patients in India: The STable Angina obseRvational (STAR) Registry
Dev Pahlajani, Upendra Kaul, Anil Mishra, et al.
Circulation. Cardiovascular Interventions
|
May 20, 2025
Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial
David E Kandzari, Felix Mahfoud, Raymond R Townsend, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension
|
October 14, 2022
Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial
Kazuomi Kario, Felix Mahfoud, David E Kandzari, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
April 10, 2020
Correction to: Rationale and design of two randomized sham‑controlled of catheter‑based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN‑OFF MED Pivotal) and presence (SPYRAL HTN‑ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
Michael Böhm, Raymond R Townsend, Kazuomi Kario, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
February 9, 2020
Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
Michael Böhm, Raymond R Townsend, Kazuomi Kario, et al.
Lancet (London, England)
|
September 21, 2022
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial
Deepak L Bhatt, Muthiah Vaduganathan, David E Kandzari, et al.
American Heart Journal
|
June 17, 2019
Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy
Elvin Kedhi, Azeem Latib, Alexandre Abizaid, et al.
JACC. Heart Failure
|
March 27, 2025
Association of Extracoronary Calcification and Incident Heart Failure in the Multiethnic Study of Atherosclerosis (MESA)
Sandeep Brar, Rahul Goli, Joshua P Barrios, et al.
Page
of 5